OTCMKTS:ATBPD Antibe Therapeutics (ATBPD) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Antibe Therapeutics Stock (OTCMKTS:ATBPD) Get Antibe Therapeutics alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage Volume29,710 shsMarket Capitalization$1.21 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Antibe Therapeutics Inc. is a Canadian biotechnology company focused on developing anti-inflammatory and analgesic medicines designed to provide the benefits of nonsteroidal anti-inflammatory drugs (NSAIDs) while reducing gastrointestinal and other safety concerns associated with conventional treatments. The company’s research is based on a hydrogen sulfide-releasing drug platform. Its lead candidate, ATB-346, is a modified form of naproxen intended to retain naproxen’s pain-relieving and anti-inflammatory properties while releasing hydrogen sulfide in the body. Antibe has also investigated additional compounds based on the same platform for potential applications in pain and inflammation. Founded in Canada, Antibe has conducted its development activities through preclinical research and clinical studies, including investigations of ATB-346 in patients with osteoarthritis and other inflammatory conditions. The company’s operations and corporate headquarters have been associated with Toronto, Ontario. Its drug candidates remain investigational and are not approved for general commercial use.AI Generated. May Contain Errors. Read More Receive ATBPD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Antibe Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ATBPD Stock News HeadlinesAntibe Therapeutics Shares Down on Clinical Hold on Otenaproxesul by U.S. RegulatorApril 1, 2024 | marketwatch.comAntibe Therapeutics Drug Otenaproxesul Placed on Clinical Hold by FDAApril 1, 2024 | marketwatch.comYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account.September 15 at 1:00 AM | Profits Run (Ad)Analysts Offer Insights on Healthcare Companies: Antibe Therapeutics (OtherATBPF), Terns Pharmaceuticals (TERN) and Aquestive Therapeutics (AQST)June 29, 2023 | markets.businessinsider.comSee More Headlines ATBPD Stock Analysis - Frequently Asked Questions How do I buy shares of Antibe Therapeutics? Shares of ATBPD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:ATBPD CIKN/A Webwww.antibethera.com Phone416 922 3460FaxN/AEmployees47Year FoundedN/AProfitability EPS (Trailing Twelve Months)($0.60) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$14.54 million Net Margins-273.96% Pretax MarginN/A Return on Equity-150.49% Return on Assets-98.51% Debt Debt-to-Equity RatioN/A Current Ratio5.97 Quick Ratio5.42 Sales & Book Value Annual Sales$7.51 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$0.10 per share Price / BookN/AMiscellaneous Outstanding Shares387,000,000Free FloatN/AMarket Cap$1.21 billion OptionableNot Optionable Beta0.57 The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (OTCMKTS:ATBPD) was last updated on 9/15/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Antibe Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Antibe Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
